Bekas K, Zafeiris C
Cureus. 2024; 16(2):e54727.
PMID: 38524011
PMC: 10960932.
DOI: 10.7759/cureus.54727.
Tucker-Bartley A, Selen D, Golden E, van Gool R, Ebb D, Mannstadt M
Int J Mol Sci. 2023; 24(3).
PMID: 36768871
PMC: 9916440.
DOI: 10.3390/ijms24032550.
Khalid S, Nunna R, Smith J, Shanker R, Cherney A, Thomson K
Acta Neurochir (Wien). 2022; 164(9):2327-2335.
PMID: 35922723
DOI: 10.1007/s00701-022-05317-4.
Davuluri S, Duvvuri B, Lood C, Faghihi-Kashani S, Chung L
Best Pract Res Clin Rheumatol. 2022; 36(2):101768.
PMID: 35803868
PMC: 10269219.
DOI: 10.1016/j.berh.2022.101768.
Rudge E, Chan A, Leeper F
RSC Med Chem. 2022; 13(4):375-391.
PMID: 35647550
PMC: 9020613.
DOI: 10.1039/d1md00297j.
RNF219/-Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications.
Zhang S, Xu Y, Xie C, Ren L, Wu G, Yang M
Adv Sci (Weinh). 2021; 8(4):2001961.
PMID: 33643786
PMC: 7887580.
DOI: 10.1002/advs.202001961.
DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine.
Meisenheimer M, Kurpig S, Essler M, Eppard E
Molecules. 2020; 25(13).
PMID: 32629930
PMC: 7412164.
DOI: 10.3390/molecules25132988.
Selection and identification of a novel bone-targeting peptide for biomedical imaging of bone.
Bang J, Park H, Yoo J, Lee D, Choi W, Lee J
Sci Rep. 2020; 10(1):10576.
PMID: 32601412
PMC: 7324617.
DOI: 10.1038/s41598-020-67522-4.
The rs1256328 (ALPL) and rs12654812 (RGS14) Polymorphisms are Associated with Susceptibility to Calcium Nephrolithiasis in a Taiwanese population.
Chen W, Chou W, Chu H, Huang C, Liu X, Chang W
Sci Rep. 2019; 9(1):17296.
PMID: 31754202
PMC: 6872875.
DOI: 10.1038/s41598-019-53261-8.
Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis.
Ono Y, Miyakoshi N, Kasukawa Y, Nagasawa H, Tsuchie H, Akagawa M
Osteoporos Sarcopenia. 2019; 4(4):128-133.
PMID: 30775555
PMC: 6372828.
DOI: 10.1016/j.afos.2018.11.085.
Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair: A review.
Qayoom I, Raina D, Sirka A, Tarasevicius S, Tagil M, Kumar A
Bone Joint Res. 2018; 7(10):548-560.
PMID: 30464835
PMC: 6215244.
DOI: 10.1302/2046-3758.710.BJR-2018-0015.R2.
The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease.
Makino T, Tsukazaki H, Ukon Y, Tateiwa D, Yoshikawa H, Kaito T
Int J Mol Sci. 2018; 19(8).
PMID: 30126106
PMC: 6121547.
DOI: 10.3390/ijms19082430.
Nanoprobes for Multimodal Visualization of Bone Mineral Phase in Magnetic Resonance and Near-Infrared Optical Imaging.
Wyss P, Herrera L, Bouteghmes N, Sarem M, Reichardt W, Leupold J
ACS Omega. 2018; 1(2):182-192.
PMID: 30023476
PMC: 6044643.
DOI: 10.1021/acsomega.6b00088.
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp A, Senn R, Curkovic I, Senn C, Buffat H, Popp P
Osteoporos Int. 2017; 28(6):1995-2002.
PMID: 28299378
DOI: 10.1007/s00198-017-3992-5.
Effect of bisphosphonate initiation at week 2 versus week 12 on short-term functional recovery after femoral neck fracture: a randomized controlled trial.
Unnanuntana A, Laohaprasitiporn P, Jarusriwanna A
Arch Osteoporos. 2017; 12(1):27.
PMID: 28283937
PMC: 5346124.
DOI: 10.1007/s11657-017-0321-8.
An Evaluative History of Bisphosphonate Drugs: Dual Physiologic Effects of Pyrophosphate as Inspiration for a Novel Pharmaceutical Class.
Hinshaw W, DeLong A
J Osteoporos. 2016; 2016:1426279.
PMID: 27800209
PMC: 5069370.
DOI: 10.1155/2016/1426279.
Targeting Cancer Cells with a Bisphosphonate Prodrug.
Matsumoto K, Hayashi K, Murata-Hirai K, Iwasaki M, Okamura H, Minato N
ChemMedChem. 2016; 11(24):2656-2663.
PMID: 27786425
PMC: 5605902.
DOI: 10.1002/cmdc.201600465.
Is there a relationship between solubility and resorbability of different calcium phosphate phases in vitro?.
Wu V, Uskokovic V
Biochim Biophys Acta. 2016; 1860(10):2157-68.
PMID: 27212690
PMC: 4961619.
DOI: 10.1016/j.bbagen.2016.05.022.
The effects of zoledronate on the survival and function of human osteoblast-like cells.
Huang K, Cheng C, Chuang P, Yang T
BMC Musculoskelet Disord. 2015; 16:355.
PMID: 26572124
PMC: 4647641.
DOI: 10.1186/s12891-015-0818-5.
Neuroprotective Effects of Etidronate and 2,3,3-Trisphosphonate Against Glutamate-Induced Toxicity in PC12 Cells.
Li W, Cheong Y, Wang H, Ren G, Yang Z
Neurochem Res. 2015; 41(4):844-54.
PMID: 26559687
DOI: 10.1007/s11064-015-1761-4.